soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Abstract 4351008: Comparing in New Users of Versus Other Noninsulin Glucose-Lowering Therapies Targeting the weight within: obesity – Oral Semaglutide Reduces Cardiovascular Events

Asia-Pacific (including Japan) - Strongest growth region supported by rising diabetic population, expanding healthcare access, increasing awareness, and large-scale pharmaceutical manufacturing in China, India, and Southeast Asia, along with Japan's advanced diabetes care ecosystem

The complexity exceeds what most independent researchers can safely manage

Bartolini, D

Amino acids serve as building blocks for proteins, including antibodies and immune cells

Specifically, no differences were detected between cases and controls groups in terms of age (p-value = 0.27), sex (p-value = 1) and median glycated hemoglobin (p-value = 0.08)